Crossmark

N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial

Crossref DOI link: https://doi.org/10.1186/s12888-018-1845-1

Published Online: 2018-09-04

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Chenghao

Bosker, Fokko J.

Li, Jie http://orcid.org/0000-0001-5408-8413
Schoevers, Robert A.
Funding

Funding for this research was provided by:

Tianjin Finance Bureau and Tianjin Key Programs for Science and Technology Development in Health Industry (No.13KG118)
License Information

Text and Data Mining valid from 2018-09-04
More Information

Article History

Received: 9 January 2018

Accepted: 13 August 2018

First Online: 4 September 2018

Ethics approval and consent to participate

: The study protocol was approved by the medical ethics committee of Tianjin Anding Hospital. All participants need to sign informed consent about the content and extent of the planned study prior to the participations. The patients’ guardians will sign the informed consent on behalf of the participants when the capacity of participants to consent is compromised.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below